Potential Plasma Biomarker Panels Identification for the Diagnosis of First-Episode Schizophrenia and Monitoring Antipsychotic Monotherapy with the Use of Metabolomics Analyses
Abstract
Schizophrenia (SCZ) is a severe mental disorder. Using liquid chromatography mass spectrometry, we performed comprehensive metabolomics analyses of plasma samples from healthy controls (HC) and first episode SCZ patients before and after an acute period of medication. Ten lipid metabolites and 27 soluble small molecules were identified as potential biomarkers associated with the diagnosis and treatment of SCZ. These metabolites were significantly reduced in SCZ, and lipids and sulfate were significantly increased after treatment. Of the metabolites identified, four showed significant correlations with the Positive and Negative Syndrome Scale total scores. A biomarker panel composed of alpha-dimorphecolic, Phosphatidylcholine (PC) (16:0/18:1(11Z)), 1-methylnicotinamide, Phosphatidylethanolamine (PE) (20:2(11Z,14Z)/18:2(9Z,12Z)), sulfate, and L-tryptophan was selected to distinguish SCZ from HC; this provided the maximum classification performance with an AUC of 0.972. A biomarker panel including C16 sphinganine, gamma-linolenic acid, linoleic acid, PC(16:0/18:1(11Z)), PE(20:2(11Z,14Z)/18:2(9Z,12Z)), and sulfate, was selected for discrimination between SCZ before and after medication, and produced the optimal classification performance with an AUC of 0.905. Disturbances in lipid metabolism, sulfation modification, tryptophan metabolism, anti-inflammatory and antioxidant systems, and unsaturated fatty acids metabolism, were identified in SCZ. Our findings could facilitate the development of objective diagnostic or drug treatment monitoring tools for schizophrenia.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Calcifediol was reduced in one observed study.
“Calcifediol was reduced in one observed study [50].”
From Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers (2024) · cites this paper as [50]
Cites
Owen, M. J., Sawa, A., & Mortensen, P. B. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01121-6 · Cited by 1,870 · see citing works
Kynurenines: Tryptophan’s metabolites in exercise, inflammation, and mental health
Cervenka, I., Agudelo, L. Z., & Ruas, J. L. (2017) · Science · doi:10.1126/science.aaf9794 · Cited by 1,382 · see citing works
The kynurenine pathway: a finger in every pie
Savitz, J. B. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0414-4 · Cited by 774 · see citing works
Roles of Peroxisome Proliferator-Activated Receptor Gamma on Brain and Peripheral Inflammation
Villapol, S. (2017) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-017-0554-5 · Cited by 372 · see citing works
Tryptophan Depletion During Continuous CSF Sampling in Healthy Human Subjects
Carpenter, L. L. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00198-x · Cited by 298 · see citing works
Selvaraj, S., Arnone, D., Cappai, A., & Howes, O. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.06.005 · Cited by 223 · see citing works
Heparan Sulfate Organizes Neuronal Synapses through Neurexin Partnerships
Zhang, P., Lu, H. P., Peixoto, R. T., Pines, M. K., Ge, Y., Oku, S., Siddiqui, T. J., Xie, Y., Wu, W., Archer‐Hartmann, S. A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.002 · Cited by 165 · see citing works
A systematic review of metabolite biomarkers of schizophrenia
Davison, J., O’Gorman, A., Brennan, L., & Cotter, D. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.09.021 · Cited by 161 · see citing works
Xuan, J., Pan, G., Qiu, Y., Yang, L., Su, M., Liu, Y., Chen, J., Feng, G., Fang, Y., Jia, W. P., et al. (2011) · Journal of Proteome Research · doi:10.1021/pr2006796 · Cited by 160 · see citing works
Self-citationPantazopoulos, H., Markota, M., Jaquet, F., Ghosh, D., Wallin, A., Santos, A., Caterson, B., & Berretta, S. (2015) · Translational Psychiatry · doi:10.1038/tp.2014.128 · Cited by 153 · see citing works
van Kruining, D., Luo, Q., van Echten‐Deckert, G., Mielke, M. M., Bowman, A. P., Ellis, S. R., Oliveira, T. G., & Martínez‐Martínez, P. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.04.009 · Cited by 136 · see citing works
Omics-Based Biomarkers: Application of Metabolomics in Neuropsychiatric Disorders
Sethi, S., & Brietzke, E. M. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv096 · Cited by 122 · see citing works
Metabolic Profiling Identifies Phospholipids as Potential Serum Biomarkers for Schizophrenia
Wang, D., Cheng, S. L., Fei, Q., Gu, H., Raftery, D., Cao, B., Sun, X., Yan, J., Zhang, C., & Wang, J. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2018.12.008 · Cited by 73 · see citing works
Pregnenolone sulfate as a modulator of synaptic plasticity
Smith, C. C., Gibbs, T. T., & Farb, D. H. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3643-x · Cited by 58 · see citing works
Profiling of Lipidomics Before and After Antipsychotic Treatment in First-Episode Psychosis
Leppik, L., Parksepp, M., Janno, S., Koido, K., Haring, L., Vasar, E., & Zilmer, M. (2018) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-018-0971-6 · Cited by 55 · see citing works
Tanaka, Y., Kume, S., Araki, H., Nakazawa, J., Chin‒Kanasaki, M., Araki, S., Nakagawa, F., Koya, D., Haneda, M., Maegawa, H., et al. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.10.414 · Cited by 54 · see citing works
Pregnenolone, Dehydroepiandrosterone, and Schizophrenia: Alterations and Clinical Trials
Ritsner, M. S. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2009.00118.x · Cited by 52 · see citing works
McCutcheon, R. A., Pillinger, T., Efthimiou, O., Maslej, M. M., Mulsant, B. H., Young, A. H., Cipriani, A., & Howes, O. D. (2022) · World Psychiatry · doi:10.1002/wps.20977 · Cited by 48 · see citing works
Suvitaival, T., Mantere, O., Kieseppä, T., Mattila, I. M., Pöhö, P., Hyötyläinen, T., Suvisaari, J., & Orešič, M. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.222 · Cited by 38 · see citing works
Cao, B., Jin, M., Brietzke, E. M., McIntyre, R. S., Wang, D., Rosenblat, J. D., Ragguett, R., Zhang, C., Sun, X., Rong, C., et al. (2018) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12779 · Cited by 37 · see citing works
Zhuo, C., Zhao, F., Tian, H., Chen, J., Li, Q., Yang, L. X., Ping, J., Li, R., Wang, L., Xu, Y. J., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01999-7 · Cited by 35 · see citing works
Alterations of eicosanoids and related mediators in patients with schizophrenia
Wang, D., Sun, X., Yan, J., Ren, B., Cao, B., Lu, Q., Liu, Y., Zeng, J., Huang, N., Xie, Q., et al. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.04.002 · Cited by 33 · see citing works
Self-citationNeuroprotective Effects of NicotinamideN‐Methyltransferase and its Metabolite 1‐Methylnicotinamide
Milani, Z. H., Ramsden, D. B., & Parsons, R. B. (2013) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.21508 · Cited by 31 · see citing works
Acute Dietary Tryptophan Depletion: Effects on Schizophrenic Positive and Negative Symptoms
Sharma, R. P., Shapiro, L. E., Kamath, S. K., Soll, E. A., Watanabe, M. D., & Davis, J. M. (2008) · Neuropsychobiology · doi:10.1159/000119323 · Cited by 30 · see citing works
Mu, R.-H., Tan, Y.-Z., Fu, L., Islam, M. N., Hu, M. Y., Hong, H., & Tang, S. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.105918 · Cited by 28 · see citing works
Severance, E. G., Leister, F. J., Lea, A., Yang, S., Dickerson, F., & Yolken, R. H. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2021.02.001 · Cited by 24 · see citing works
Shang, P., Ho, A. M., Tufvesson‐Alm, M., Lindberg, D. R., Grant, C. W., Orhan, F., Eren, F., Bhat, M., Engberg, G., Schwieler, L., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02000-1 · Cited by 22 · see citing works
Rajagopal, L., Soni, D., & Meltzer, H. Y. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.05.005 · Cited by 21 · see citing works
García, C. J., Yang, X., Huang, D., & Tomás-Barberán, F. A. (2020) · Metabolomics · doi:10.1007/s11306-020-01705-y · Cited by 20 · see citing works
A Metabolomics Study of Serum in Hospitalized Patients With Chronic Schizophrenia
Okamoto, N., Ikenouchi, A., Watanabe, K., Igata, R., Fujii, R., & Yoshimura, R. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.763547 · Cited by 20 · see citing works
Constituents ofLimonia acidissimainhibit LPS-induced nitric oxide production in BV-2 microglia
Kim, K. H., Ha, S. K., Kim, S. Y., Youn, H. J., & Lee, K. R. (2010) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756360903514156 · Cited by 19 · see citing works
Kim, S., Okazaki, S., Otsuka, I., Shinko, Y., Horai, T., Shimmyo, N., Hirata, T., Yamaki, N., Tanifuji, T., Boku, S., et al. (2021) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12223 · Cited by 17 · see citing works
Smith, C. C., Martin, S. C., Sugunan, K., Russek, S. J., Gibbs, T. T., & Farb, D. H. (2014) · Molecular Pharmacology · doi:10.1124/mol.114.094128 · Cited by 15 · see citing works
Serum PGE2, 15d-PGJ, PPARγ and CRP levels in patients with schizophrenia
Yüksel, R. N., Titiz, A. P., YAYLACI, E. T., Ünal, K., Turhan, T., Erzın, G., Züngün, C., Aydemır, M. Ç., & Göka, E. (2019) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2019.09.026 · Cited by 14 · see citing works
Yukawa, T., Iwakura, Y., Takei, N., Saito, M., Watanabe, Y., Toyooka, K., Igarashi, M., Niizato, K., Oshima, K., Kunii, Y., et al. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.10.062 · Cited by 12 · see citing works
Zhao, J., Zhang, Y., Liu, Y., Tang, W., Ji, C.-H., Gu, J., & Jiang, B. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.135535 · Cited by 12 · see citing works
Self-citationGurke, R., Etyemez, S., Prvulovic, D., Thomas, D., Fleck, S. C., Reif, A., Geißlinger, G., & Lötsch, J. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00041 · Cited by 11 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
De Simone, G., Mazza, B., Vellucci, L., Barone, A., Ciccarelli, M., & de Bartolomeis, A. (2023) · Antioxidants · doi:10.3390/antiox12040975 · Cited by 49 · see citing works
Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers
Zorkina, Y., Ushakova, V., Ochneva, A., Tsurina, A., Abramova, O., Savenkova, V., Goncharova, A., Alekseenko, I., Morozova, I., Riabinina, D., et al. (2024) · Metabolites · doi:10.3390/metabo14020080 · Cited by 36 · see citing works
- Authors
- Song, M., Liu, Y., Zhou, J., Shi, H., Su, X., Shao, M., Yang, Y., Wang, X., Zhao, J., Guo, D., Liu, Q., Zhang, L., Zhang, Y., Lv, L., & Li, W.
- Affiliations
- Henan Psychiatric Hospital (CN)
- Corresponding author
- Song, Meng
- Lv, Luxian
- Li, Wenqiang
- Venue
- Psychiatry Research
- Publisher
- Elsevier BV
- Published
- 2023-03
- Volume
- 321
- Pages
- 115070
- ISSN
- 0165-1781 (ISSN-L)
- OpenAlex
- W4318391275
- Cited by
- 32
- References
- 37
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 10 · 2023: 6
- FWCI
- 2.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Psychiatry Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- schizophrenia, first-episode schizophrenia, plasma metabolomics, antipsychotic monotherapy, treatment response monitoring, lipid metabolism, sulfate metabolism, tryptophan metabolism, phosphatidylcholine, phosphatidylethanolamine, sphinganine, gamma-linolenic acid, linoleic acid, unsaturated fatty acids, diagnostic biomarkers
- MeSH terms
- Humans, Schizophrenia, Mass Spectrometry, Antipsychotic Agents, Biomarkers, Metabolomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
